Treatment of angiopoietin like 7 (angptl7) related diseases
AssigneeEmpirico Inc.
InventorsOmri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David LEWIS, David ROZEMA
Life of this patent
Estimating the term…
Abstract
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Claims20
A composition comprising an oligonucleotide that targets Angiopoietin like 7 (ANGPTL7) and when administered to a cell decreases expression of ANGPTL7, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NOs:
- 1424, 1541, 2091 in which at least one internucleoside linkage is modified and at least one base is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside, substitutions, additions, or deletions of SEQ ID NOs:
- 1424, 1541, or 2091 in which at least one internucleoside linkage is modified and at least one base is modified, and wherein the antisense strand comprises an oligonucleotide sequence of SEQ ID NOs:
- 3630, 3747, or 4297 in which at least one internucleoside linkage is modified and at least one base is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside, substitutions, additions, or deletions of SEQ ID NOs:
- 3630, 3747, or 4297 in which at least one internucleoside linkage is modified and at least one base is modified.
A pharmaceutical composition comprising
- (a) an oligonucleotide that targets Angiopoietin like 7 (ANGPTL7) and when administered to a cell decreases expression of ANGPTL7, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NOs:
- 1424, 1541, 2091 in which at least one internucleoside linkage is modified and at least one base is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside, substitutions, additions, or deletions of SEQ ID NOs:
- 1424, 1541, or 2091 in which at least one internucleoside linkage is modified and at least one base is modified, and wherein the antisense strand comprises an oligonucleotide sequence of SEQ ID NOs:
- 3630, 3747, or 4297 in which at least one internucleoside linkage is modified and at least one base is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside, substitutions, additions, or deletions of SEQ ID NOs:
- 3630, 3747, or 4297 in which at least one internucleoside linkage is modified and at least one base is modified;
- and
- (b) a pharmaceutically acceptable carrier.
A composition comprising an oligonucleotide that targets Angiopoietin like 7 (ANGPTL7) and when administered to a subject in an effective amount decreases intraocular pressure, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, the antisense strand being complementary to a portion of a nucleic acid having the nucleoside sequence of SEQ ID NO:
- 11085, and each strand having 14 to 30 nucleotides, and wherein the oligonucleotide comprises a lipid attached at a 3′ or 5′ terminus of the oligonucleotide.
Dependencies are inferred from the claim text.